For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- MHLW Panel Discusses 6 Risks to Drug Supplies; Need for Industry Consolidation Raised
June 21, 2023
- MHLW to Set Up Separate Forums Focused on Generics and Drug Lags to Execute Expert Panel Proposals
June 21, 2023
- Ryukaikon to Meet June 26 to Discuss Expert Panel Proposals
June 21, 2023
- MHLW Study Group to Develop Company Indicators for Generic Supply Systems in FY2023
June 20, 2023
- Relief Claims OK’ed for 5 More Deaths Possibly Linked to COVID Jabs
June 20, 2023
- MHLW Study Group Proposes Flexibility in Launch Premium Criteria, Broader Comparators
June 20, 2023
- MHLW Starts Clinical Study on Mpox Vaccine for People with High Infection Risks
June 19, 2023
- PMDA to Establish Asia, US Hubs to Spur Innovative Drug Development
June 19, 2023
- Japan OKs Honebuto Budget Policy Blueprint, Vows Debates on Longer-Term Drug Costs
June 19, 2023
- Democratic Party For the People Calls for Drug Pricing Overhaul
June 16, 2023
- First Generics for 11 APIs to Enter NHI Price List, Azilva Faces Most Contenders
June 15, 2023
- MSD’s Lyfnua Braces for Price Cuts under CEA Scheme
June 15, 2023
- Japan Diet Clears Lawmaker-Sponsored Dementia Bill
June 15, 2023
- MHLW Mulls New OTC Class to Bar Online Sales amid Unease over Morning After Pills
June 14, 2023
- LDP Policy Research Council Generally Approves Revised Honebuto Draft
June 14, 2023
- Label Revision Ordered for Opdivo, Yervoy to Add Meningitis Risks
June 14, 2023
- MHLW to Set Up Team Dedicated to Executing Healthcare DX Timeline
June 13, 2023
- 3 Japan Manufacturers of Plasma-Derived Products Call for Changes in Export Rules: PAFSC Committee
June 13, 2023
- Panelist Suggested Macroeconomic Indexing for Social Security Spending: CEFP Minutes
June 13, 2023
- MHLW Publishes Final Report by Expert Panel on Comprehensive Pharma Policy
June 13, 2023
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…